Supernus Pharmaceuticals Inc

S49

Company Profile

  • Business description

    Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

  • Contact

    9715 Key West Avenue
    RockvilleMD20850
    USA

    T: +1 301 838-2500

    E: [email protected]

    https://www.supernus.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    778

Stocks News & Analysis

stocks

Anthropic and OpenAI face commodification threats. Here’s what to watch for

Frontier AI labs face a three-pronged set of challenges.
stocks

Berkshire Hathaway: Abel pushes into new territory with Bending Spoons investment

We think it is a sign that the firm is finally moving out of its comfort zone to find places to put capital to work.
stocks

Overlooked cheap ASX share

The market may be overlooking this share’s long-term value.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,962.1021.700.24%
CAC 407,956.7022.000.28%
DAX 4025,622.61239.990.95%
Dow JONES (US)52,002.41175.28-0.34%
FTSE 10010,881.9041.550.38%
HKSE24,186.83124.110.52%
NASDAQ26,140.03572.99-2.14%
Nikkei 22564,128.531,195.76-1.83%
NZX 50 Index13,674.7478.99-0.57%
S&P 5007,659.4484.62-1.09%
S&P/ASX 2008,833.6026.900.31%
SSE Composite Index3,716.288.810.24%

Market Movers